C-MER Medical completes Series B investment; secures 10.23% stake in CHIGENOVO and perpetual exclusive rights to ZVS101e

Bulletin Express

Aug 10

C-MER Medical Holdings Limited announced the completion of its Series B investment in Beijing-based CHIGENOVO Co., Ltd. following the satisfaction or waiver of all conditions precedent outlined in earlier agreements dated 20 May 2026 and 30 June 2026. Through its wholly owned subsidiary HK (International) Eye Care, C-MER Medical now holds 996,070 shares—representing approximately 10.23% of CHIGENOVO’s enlarged issued share capital.

The Legally Binding Agreement provides C-MER Medical with perpetual exclusive rights to ophthalmology product ZVS101e in Hong Kong and Macau, effective upon receipt of approvals from the National Medical Products Administration and relevant local authorities. Revenue sharing terms guarantee the Group economics that are at least as favorable as any comparable agreements CHIGENOVO may conclude for ZVS101e. Any disputes under the agreement will be referred to mediation at the Hong Kong International Arbitration Centre.

Despite the equity stake, C-MER Medical will not consolidate CHIGENOVO’s financial results into its accounts, indicating a non-controlling, minority investment structure.

The Board confirmed transaction completion on 10 August 2026, with Vice Chair, Executive Director and CEO Ms. Li Xiaoting signing on behalf of C-MER Medical.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1107864961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1107864961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1107864961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107864961","market":"us","top_or_hot":-1,"title":"C-MER Medical completes Series B investment; secures 10.23% stake in CHIGENOVO and perpetual exclusive rights to ZVS101e","media":"Bulletin Express","content":"<p>C-MER Medical Holdings Limited announced the completion of its Series B investment in Beijing-based CHIGENOVO Co., Ltd. following the satisfaction or waiver of all conditions precedent outlined in earlier agreements dated 20 May 2026 and 30 June 2026. Through its wholly owned subsidiary HK (International) Eye Care, C-MER Medical now holds 996,070 shares—representing approximately 10.23% of CHIGENOVO’s enlarged issued share capital.</p>\n<p>The Legally Binding Agreement provides C-MER Medical with perpetual exclusive rights to ophthalmology product ZVS101e in Hong Kong and Macau, effective upon receipt of approvals from the National Medical Products Administration and relevant local authorities. Revenue sharing terms guarantee the Group economics that are at least as favorable as any comparable agreements CHIGENOVO may conclude for ZVS101e. Any disputes under the agreement will be referred to mediation at the Hong Kong International Arbitration Centre.</p>\n<p>Despite the equity stake, C-MER Medical will not consolidate CHIGENOVO’s financial results into its accounts, indicating a non-controlling, minority investment structure.</p>\n<p>The Board confirmed transaction completion on 10 August 2026, with Vice Chair, Executive Director and CEO Ms. Li Xiaoting signing on behalf of C-MER Medical.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>C-MER Medical completes Series B investment; secures 10.23% stake in CHIGENOVO and perpetual exclusive rights to ZVS101e</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nC-MER Medical completes Series B investment; secures 10.23% stake in CHIGENOVO and perpetual exclusive rights to ZVS101e\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-10 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>C-MER Medical Holdings Limited announced the completion of its Series B investment in Beijing-based CHIGENOVO Co., Ltd. following the satisfaction or waiver of all conditions precedent outlined in earlier agreements dated 20 May 2026 and 30 June 2026. Through its wholly owned subsidiary HK (International) Eye Care, C-MER Medical now holds 996,070 shares—representing approximately 10.23% of CHIGENOVO’s enlarged issued share capital.</p>\n<p>The Legally Binding Agreement provides C-MER Medical with perpetual exclusive rights to ophthalmology product ZVS101e in Hong Kong and Macau, effective upon receipt of approvals from the National Medical Products Administration and relevant local authorities. Revenue sharing terms guarantee the Group economics that are at least as favorable as any comparable agreements CHIGENOVO may conclude for ZVS101e. Any disputes under the agreement will be referred to mediation at the Hong Kong International Arbitration Centre.</p>\n<p>Despite the equity stake, C-MER Medical will not consolidate CHIGENOVO’s financial results into its accounts, indicating a non-controlling, minority investment structure.</p>\n<p>The Board confirmed transaction completion on 10 August 2026, with Vice Chair, Executive Director and CEO Ms. Li Xiaoting signing on behalf of C-MER Medical.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03309","symbol_name":"希玛医疗","start_time":0,"source_url":"","article_id":"1107864961","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107864961","pubTimestamp":1786356369,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"C-MER Medical Holdings Limited announced the completion of its Series B investment in Beijing-based CHIGENOVO Co., Ltd. following the satisfaction or waiver of all conditions precedent outlined in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03309":"希玛医疗"},"translate_title":"C-MER Medical完成B轮投资；获得 CHIGENOVO 10.23% 的股权以及 ZVS101e 的永久独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03309":1},"content_text":"C-MER Medical Holdings Limited announced the completion of its Series B investment in Beijing-based CHIGENOVO Co., Ltd. following the satisfaction or waiver of all conditions precedent outlined in earlier agreements dated 20 May 2026 and 30 June 2026. Through its wholly owned subsidiary HK (International) Eye Care, C-MER Medical now holds 996,070 shares—representing approximately 10.23% of CHIGENOVO’s enlarged issued share capital.\nThe Legally Binding Agreement provides C-MER Medical with perpetual exclusive rights to ophthalmology product ZVS101e in Hong Kong and Macau, effective upon receipt of approvals from the National Medical Products Administration and relevant local authorities. Revenue sharing terms guarantee the Group economics that are at least as favorable as any comparable agreements CHIGENOVO may conclude for ZVS101e. Any disputes under the agreement will be referred to mediation at the Hong Kong International Arbitration Centre.\nDespite the equity stake, C-MER Medical will not consolidate CHIGENOVO’s financial results into its accounts, indicating a non-controlling, minority investment structure.\nThe Board confirmed transaction completion on 10 August 2026, with Vice Chair, Executive Director and CEO Ms. Li Xiaoting signing on behalf of C-MER Medical.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}